This approach was evaluated in a phase I/II clinical trial where HLA-mismatched UCB-derived CAR-NK cells targeting CD19 were infused in 11 patients with relapsed or refractory CD19-positive B cell NHL or CLL. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.